1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 4.1.1. Market Research Process 4.1.2. Research Design 4.1.3. Research Methodology 5. Scope of the Report Market Overview Product Offerings 6. Market Landscape 6.1. Market Size and Forecast 6.2. Market Segmentation Based on Product Type 6.3. Market Segmentation Based on Application 6.4. Market Segmentation Based on Technology 6.5. Five Force Analysis 7. Geographical Segmentation 8. Vendor Landscape 9. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 15.1. Abbott Laboratories 15.1.1. Business Overview 15.1.2. Key Information 15.1.3. SWOT Analysis 15.2. Becton, Dickinson and Co. 15.2.1. Business Overview 15.2.2. Key Information 15.2.3. SWOT Analysis 15.3. QIAGEN N.V. 15.3.1. Business Overview 15.3.2. Key Information 15.3.3. SWOT Analysis 15.4. Roche Holding Ltd. 15.4.1. Business Overview 15.4.2. Key Information 15.4.3. SWOT Analysis 16. Other Reports in this Series List of Exhibits: Exhibit 1: Market Research Methodology Exhibit 2: Global Molecular Diagnostics Market 2012-2016 (US$ billion) Exhibit 3: Global Molecular Diagnostics Market Segmentation Exhibit 4: Global Molecular Diagnostics Market Segmentation Based on Application Exhibit 5: Global Molecular Diagnostics Market Segmentation Based on Application 2012 Exhibit 6: Global Molecular Diagnostics Market Segmentation Based on Technology Exhibit 7: Global Molecular Diagnostics Market Segmentation Based on Technology 2012 Exhibit 8: Global Molecular Diagnostics Market by Geographical Segmentation 2012 Exhibit 9: Global Molecular Diagnostics Market by Vendor Segmentation 2012 Exhibit 10: Key Mergers and Acquisitions in the Global Molecular Diagnostics Market Exhibit 11: Business Segmentation of Abbott Laboratories Exhibit 12: Business Segmentation of Becton, Dickinson and Co. Exhibit 13: Business Segmentation of QIAGEN N.V. Exhibit 14: Business Segmentation of Roche Holding Ltd.

Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., Roche Holding Ltd., Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck & Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc.